Psychiatrists
Adherence, Long-Acting Injectable, Recovery, Schizophrenia
Christoph U. Correll, MD, is professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, both in New York. He is further the director of the Adverse Events Unit and the Core Laboratory Unit at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research. 
John M. Kane, MD, is Vice President for Behavioral Health Services at North Shore University Hospital of the Long Island Jewish Heath System and he is Chairman of the Department of Psychiatry and Chief of Staff at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane is also a professor of psychiatry, neuroscience, and neurology and the Dr. E. Richard Feinberg Chair in Schizophrenia Research at Albert Einstein College of Medicine in New York, New York as well as Professor and Chair, Department of Psychiatry and the Department of Molecular Medicine at Hofstra North Shore-LIJ School of Medicine.
In June 2009, Dr. Lauriello became only the third permanent chair of the University of Missouri Department of Psychiatry in its 50 year history. Dr. Lauriello holds the University of Missouri Chancellor's Chair of Excellence in Psychiatry. Under his leadership he has overseen the opening of the University of Missouri Psychiatric Center; formerly an acute care state facility it is widely regarded as the psychiatric center of excellence for the Mid Missouri region.| 1. | Discuss the prevalence and consequences of nonadherence among patients with schizophrenia | 2. | Integrate evidence-based medical and non-medical interventions for improved schizophrenia treatment adherence into daily practice | 
| 3. | Evaluate and interpret efficacy, safety, and outcomes data for LAI antipsychotics for schizophrenia | 4. | Select the most appropriate patients for LAI intervention | 
| 5. | Institute discussions with patients that include incorporating LAIs as a potential management option | 
| 1. | Discuss the prevalence and consequences of nonadherence among patients with schizophrenia | 
| 2. | Integrate evidence-based medical and non-medical interventions for improved schizophrenia treatment adherence into daily practice | 
| 3. | Evaluate and interpret efficacy, safety, and outcomes data for LAI antipsychotics for schizophrenia | 
| 4. | Select the most appropriate patients for LAI intervention | 
| 5. | Institute discussions with patients that include incorporating LAIs as a potential management option | 
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime.  |  Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above  |